UCART-2

N/A

Report date: 2025/01/26 16:35:41

Base Information

Drug NameUCART-2

Drug Alias Nameanti-CD2 CAR T-cell therapy (Wugen/Washington University)UCART-2

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionLymphocyte function-associated antigen 3 modulators

TargetsLymphocyte function-associated antigen 3

Therapy Area/IndicationsSezary SyndromeLymphoma, T-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesWugen Inc

China Registration ClassN/A

Develop Information

Active CompaniesWugen Inc

Inactive CompaniesN/A

Active IndicationsSezary SyndromeLymphoma, T-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A